Kyriazopoulou, Evdoxia
Leventogiannis, Konstantinos
Tavoulareas, Georgios
Mainas, Efstratios
Toutouzas, Konstantinos
Mathas, Christos
Prekates, Athanassios
Sakka, Vissaria
Panagopoulos, Periklis
Syrigos, Konstantinos
Giamarellos-Bourboulis, Evangelos J.
Funding for this research was provided by:
Hellenic Institute for the Study of Sepsis
Seventh Framework Programme (611682)
Article History
Received: 21 March 2022
Accepted: 1 March 2023
First Online: 7 March 2023
Competing interests
: P. Panagopoulos has received honoraria from GILEAD Sciences, Janssen, and MSD. G. Poulakou has received independent educational grants from Pfizer, MSD, Angelini, and Biorad. E.J. Giamarellos-Bourboulis has received honoraria from AbbVie USA, Abbott CH, Brahms GmbH, InflaRx GmbH, MSD Greece, Sobi and XBiotech Inc.; independent educational grants from Abbott, bioMérieux Inc, Johnson & Johnson, InflaRx GmbH, Sobi; and funding from the Horizon2020 Marie-Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens), and the Horizon 2020 European Grant ImmunoSep and RISCinCOVID (granted to the Hellenic Institute for the Study of Sepsis). All other authors have disclosed that they do not have any conflicts of interest relevant to this submission.